-
From April 10 to 13, 2024 (local time), the 44th Annual Conference of the International Society for Heart and Lung Transplantation (ISHLT 2024) was held at the Prague Congress Centre in the Czech Republic. At the ISHLT session titled “Spin Doctors and Heart Hotties: Unleashing the Future of MCS Devices,” Professor Wang Xianqiang from Fuwai Hospital made the first-ever international presentation of the long-term follow-up results for CH-VAD.
-
On August 7, People’s Daily published an article titled Domestic Fully Magnetically Levitated VAD Serving Patients, commending CH Biomedical for breaking the international technological monopoly for developing a domestically produced, fully magnetically levitated VAD with independent intellectual property rights. The device is currently available in nearly 40 hospitals across China, enabling over 140 patients with advanced heart failure to embark on a “new life”.
-
CH Biomedical, recognized as a pioneering innovator in the global Ventricular Assist Device (VAD) field, earned a place on MIT Technology Review’s 2021 “50 Smartest Companies” list for its CH-VAD, a next-generation, fully magnetically levitated implantable left ventricular assist system (LVAD) — the first of its kind in China to be independently developed and approved by the National Medical Products Administration (NMPA).
-
Recently, CH Biomedical, a technological pioneer in the global Ventricular Assist Device (VAD) field, successfully obtained ISO 13485:2016 certification from the authoritative third-party certifier BSI (Certificate No.: MD 758952). This achievement confirms that the company has achieved internationally standardized excellence across the design, development, manufacturing, and post-marketing quality management of its VAD products.
-
May 24-27, 2022 International Society for Mechanical Circulatory Society (ISMCS) and European Mechanical Circulatory Society (EUMS) Joint Scientific Conference was successfully held in Hanover, Germany. Dr. Frank Lin, PhD, CTO of CH Biomedical, and Mr. Karl Nelson, Vice President of Clinical Operations were invited to attend the conference.
-
Recently, at the 2022 China Medical Development Conference—widely regarded as the country’s premier medical forum—the Chinese Academy of Medical Sciences (CAMS) released two lists: China’s Major Medical Achievements of the 21st Century and China’s Important Medical Advancements in 2021. As a global innovator in the field of Ventricular Assist Devices (VADs), CH Biomedical’s independently developed CH-VAD (NMPA (A) 20213120987) was included in China’s Important Medical Advancements in 2021.
